Cutaneous castleman's disease responds to anti interleukin-6 treatment.

• Abstract: Castleman's disease is uncommon, and cutaneous involvement is even rarer. We report a 42-year-old Asian woman with the multicentric plasma cell variant of Castleman's disease limited to her skin. The literature suggests that Castleman's disease is driven by interleukin-6 (IL-6). Based on these data, we hypothesized that suppression of IL-6 would have a salutary effect. Therefore, our patient was treated with CNTO328, a chimeric murine anti-human IL-6 antibody. She has shown a remarkable, ongoing response to this treatment, with almost complete clearing of her skin lesions after six doses.
• Authors: Bilal Ahmed, Jaime A Tschen, Philip R Cohen, Mohamed H Zaki, Peter L Rady, Stephen K Tyring, Robert E Corringham, Razelle Kurzrock (Affiliation: Phase I Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 422, Houston, TX 77030, USA. rkurzroc at mdanderson.org)
• Journal: Molecular cancer therapeutics (Mol Cancer Ther) Vol. 6 Issue 9 Pg. 2386-90 (Sep 2007) ISSN: 1535-7163 [Print] United States
• PMID: 17766835 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal
• Interleukin-6

Topics

• Adult
• Antibodies, Monoclonal (immunology, therapeutic use)
• Female
• Giant Lymph Node Hyperplasia (drug therapy, immunology, pathology)
• Humans
• Interleukin-6 (chemistry, immunology, therapeutic use)
• Plasma Cells (drug effects, immunology, pathology)
• Prognosis
• Skin Neoplasms (drug therapy, immunology, pathology)